Financial Results Announcement - Clarivate Plc will report its financial results for the second quarter of 2025 before the market opens on July 30, 2025 [1] - The press release and earnings supplement will be available on the Clarivate investor website [1] Conference Call Details - The company will host a conference call and webcast at 9:00 AM Eastern Time on July 30, 2025, to review the results [2] - The webcast is open to all interested parties and may include forward-looking information [2] Access Information - Interested parties can access the live audio broadcast via specific phone numbers for U.S. and international participants [3] - A replay of the webcast will be available on the investor relations website starting two hours after the live call and will remain accessible for one year [3] Company Overview - Clarivate is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services in various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare [4]

Core Insights - Clarivate Plc has released the 2025 update to the Journal Citation Reports (JCR), marking the 50th anniversary of these influential annual reports that assess the trustworthiness and impact of academic journals [1][3] Company Overview - Clarivate is recognized as a leading global provider of transformative intelligence, offering enriched data, insights, analytics, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare [6] JCR Highlights - The 2025 JCR includes data from 22,249 journals across 254 categories, with over 6,200 published via gold open access [6] - Scholarly journals from 111 countries are acknowledged, with 14,591 in the sciences, 7,559 in social sciences, and 3,368 in arts and humanities [6] - This year, 618 journals received a Journal Impact Factor (JIF) for the first time [6] - The calculation of JIF now excludes citations to and from retracted content, ensuring that such citations do not affect the JIF numerator, although retracted articles remain in the article count for transparency [6]

Core Insights - The report by Clarivate Plc highlights emerging companies in the field of radioligand therapies (RLTs) that are transforming cancer care through precision oncology innovations [1][3] - RLTs are gaining traction as a promising approach in oncology, delivering radioactive isotopes directly to tumor cells while minimizing harm to healthy tissues [2][3] Company Highlights - **Affibody**: A clinical-stage biopharmaceutical company focused on oncology and immunology, utilizing its proprietary Affibody® technology platform to develop next-generation biopharmaceutical drugs [4] - **Alpha-9 Oncology**: Developing targeted radiopharmaceuticals for various malignancies, leveraging expertise in peptide and small molecule modifications [4] - **Ariceum Therapeutics**: Focused on radiopharmaceutical theranostic pairs for aggressive tumors, with its lead product satoreotide targeting somatostatin receptor 2 [4] - **Convergent Therapeutics**: Developing radioantibodies for cancer treatment, with its lead candidate in phase 2 trials for metastatic castration-resistant prostate cancer [5] - **Perspective Therapeutics**: Employing a theranostic approach with proprietary chelator technology for radiolabeling targeting moieties against cancers [9] - **PRECIRIX®**: Developing radiopharmaceutical theranostics using camelid single-domain antibodies against multiple targets, focusing on FAP-positive tumors [9] Market Trends - The global radiopharmaceutical market is projected to exceed $13 billion within the next decade, indicating significant growth potential for companies in this sector [7] - Notable acquisitions in the RLT field include Bristol Myers Squibb's $4.1 billion acquisition of RayzeBio and AstraZeneca's $2.4 billion acquisition of Fusion Pharmaceuticals, reflecting strategic investments in this area [6] Research and Development Insights - The report provides a comprehensive overview of the RLT landscape, including scientific advancements, clinical potential, and market dynamics [3] - It emphasizes the importance of differentiated R&D strategies and intellectual property positioning in setting companies apart in the competitive landscape [3][8]

Core Insights - Clarivate Plc has become the first sponsor of the American Library Association's (ALA) Public Supporter Program, marking a significant milestone in their partnership [1][5] - The Public Supporter Program, launched on February 10, 2025, aims to engage the public in supporting libraries and provides resources for library advocacy [3][5] - Clarivate's contributions will support key ALA initiatives and run for two years, until 2027 [5] Company Overview - Clarivate is a leading global provider of transformative intelligence, offering data, insights, analytics, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare [6] - The company emphasizes the importance of libraries in education, research, and access to information [4] Industry Context - The ALA is the largest library association globally, advocating for libraries and library professionals across diverse settings, from small rural libraries to large systems [2] - The ALA is a nonprofit, nonpartisan organization dedicated to enhancing learning and ensuring access to information for all [6][7]

Core Insights - Clarivate Plc has announced a multi-year partnership with the Canadian Research Knowledge Network (CRKN) to provide expanded access to the Web of Science for 55 Canadian universities, enhancing research collaborations and accessibility [1][4]. Company Overview - Clarivate is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare [5]. Industry Impact - The partnership aims to support Canadian researchers by providing access to the Web of Science API, which includes rich metadata to aid research projects, as well as access to the Derwent Innovations Index and the Policy Citation Index to understand the societal impact of research outputs [3][4]. - Canada is recognized for its collaborative position in global academic research, with contributions in innovation and patents exceeding the international average [4].

Core Viewpoint - Clarivate Plc has successfully completed an incremental upsize of its term loan B credit facility, taking advantage of improved credit market conditions to extend the maturity of its 2026 debt [1][3]. Financial Summary - The company incurred a new $500 million tranche of incremental term loans maturing in 2031, with an interest rate margin of 325 basis points per annum, and these loans will not be subject to amortization [2]. - The proceeds from the new term loans were used to redeem $500 million of the outstanding 4.50% senior secured notes due 2026, leaving $200 million of the notes remaining outstanding after the partial redemption [2]. Management Commentary - The Executive Vice President and Chief Financial Officer of the company expressed satisfaction with the ability to extend the majority of the 2026 debt maturity, highlighting the company's strong cash flow and flexibility in capital allocation moving forward [3].

Core Insights - Clarivate Plc has renewed its partnership with CAPES, significantly expanding access to academic and life sciences data across over 400 Brazilian institutions, increasing institutional coverage by 57% compared to the previous contract [1][2][6] - The partnership aims to democratize access to critical scientific information, enabling researchers and practitioners to conduct innovative research and improve patient care [3][4][6] - The agreement enhances access to various research tools, including Web of Science, Journal Citation Reports, and Cortellis Drug Discovery Intelligence, supporting evidence-based discovery and decision-making [2][5][6] Company and Industry Impact - The collaboration with CAPES reflects a commitment to advancing scientific excellence and reducing regional disparities in Brazil's research landscape [4][6] - The expanded access to trusted research tools is expected to strengthen postgraduate programs and elevate the global visibility of Brazilian research [6][7] - Brazil's research output shows a strong focus on Sustainable Development Goals, particularly in Life Sciences and Medicine, with a notable emphasis on international collaboration [10]

Core Insights - Clarivate Plc has launched RiskMark, an AI-powered solution designed to help trademark professionals evaluate trademark risk and generate evidence-backed arguments efficiently [1][4] - RiskMark utilizes a vast database of 172.5 million trademark records and over 5 million global court and administrative records to assess similarity risk [2] - The solution employs generative and predictive AI to provide near-instant results on various aspects of trademark evaluation, enhancing decision-making speed and confidence [2] Company Overview - Clarivate is recognized as a leading global provider of transformative intelligence, offering data, insights, analytics, and expert services across multiple sectors including Intellectual Property [5] - The company aims to empower IP professionals with trustworthy AI-driven insights to assess risk and streamline the drafting process for trademark-related arguments [4]

Q1 2021 Earnings Supplemental Materials April 29, 2021 Forward-Looking Statements These materials contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, outlook, anticipated cost savings, anticipa ...

Transaction Overview - Clarivate will acquire ProQuest for $5.3 billion [9], including refinancing approximately $1.0 billion of ProQuest's net debt [9] - ProQuest shareholders will receive approximately $1.3 billion of Clarivate shares, representing about 7% combined ownership, and approximately $3.0 billion in cash [9] - The transaction is expected to close in Q3 2021 [9] Financial Highlights (Combined Business) - The combined adjusted revenue for 2020 is approximately $2.6 billion [6, 10] - The combined adjusted EBITDA for 2020 is approximately $1.2 billion [10] with adjusted EBITDA margins of approximately 45% [10] - The combined adjusted EBITDA less CapEx for 2020 is approximately $1.0 billion [10] - Clarivate anticipates double-digit adjusted diluted EPS accretion in 2022 and mid-teens accretion in 2023 [6, 10, 40] Synergies and Cost Savings - The acquisition is expected to generate more than $100 million in run-rate cost savings [9, 10, 36, 44] and $10 million in CapEx synergies [10, 36] - These cost savings are expected to be fully realized within 15-18 months [10, 39, 44] ProQuest Overview - ProQuest has access to >5 million Dissertations [15], 20 million pages of newspapers [15], >6 Billion Digital Pages [15], 285 million Journal Articles [15], Data on 40 million Books [15], > 450,000 eBooks [15] - ProQuest's 2020 revenue was $876 million [22] with a 4% organic growth rate [22] - ProQuest's adjusted EBITDA was $253 million [22] with a 30% margin [22]